Prospective, Randomized, Double-Blind, Vehicle Controlled, Multicenter Phase IIb Clinical Trial of the Pore Forming Protein PRX302 for Targeted Treatment of Symptomatic Benign Prostatic Hyperplasia

Journal of Urology - Netherlands
doi 10.1016/j.juro.2012.11.003
Full Text
Abstract

Available in full text

Categories
Urology
Date
Authors
Publisher

Ovid Technologies (Wolters Kluwer Health)


Related search